TRISALUS LIFE SCIENCES, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.72 USD | -3.38% |
|
-0.87% | -32.31% |
| 06-03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
| 05-30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
